Last reviewed · How we verify
NCT06893328: PMNTRWS
A Real World Study About PMN
trial in Primary Membranous Nephropathy in 200 participants. Currently enrolling.
11 November 2027
Quick facts
| Lead sponsor | Wei Chen |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 11 November 2024 |
| Primary completion | 11 November 2027 |
| Estimated completion | 11 November 2027 |
| Sites | 1 location across China |
Conditions studied
- Primary Membranous Nephropathy — all drugs for Primary Membranous Nephropathy →
Sponsor
Wei Chen
Who can join
18 and older, any sex, with Primary Membranous Nephropathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators designed a randomized, controlled, multicenter clinical study to compare the efficacy and safety of rituximab combined with hormones versus rituximab monotherapy in the treatment of primary membranous nephropathy. At the same time, the investigators conducted a real-world study on patients who did not meet the inclusion and exclusion criteria or were unwilling to enter the RCT cohort, to further observe the trial results in a broader population.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06893328
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Primary Membranous Nephropathy
Currently open trials in the same condition.
- NCT07204275 — A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropat · Phase 2, PHASE3 · recruiting
- NCT07157787 — Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN) · Phase 2 · recruiting
- NCT06962800 — A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropath · Phase 3 · recruiting
- NCT06642909 — A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy · Phase 2 · active not recruiting
- NCT06781944 — OBINOTUZUMAB Versus Cyclophosphamide + Glucocorticoids in Primary Membranous Nephropathy(Blossom Study) · Phase 3 · recruiting
Other Wei Chen trials
Trials by the same sponsor.
- NCT07098416 — A Real-World Study About Anemia in Chronic Kidney Disease in China（DASHENG） · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06893328 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Wei Chen
- Last refreshed: 22 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06893328.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing